Manfred Reichl

HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria.

HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria.

HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria.

HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.